Research has identified a combination of IAP antagonist and IFNγ that activates novel cell death pathways. The pathways involved appear to include caspase-10 and RIPK1, although other factors such as TNF-α and JAK1/2-STAT1 may also play a role in certain cell types. The discovery of these pathways may have implications for understanding and targeting cancer, particularly in relation to immune response and tumor protection.